Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Loss of myostatin attenuates severity of muscular dystrophy in mdx mice.

Literature DB >> 12447939

Loss of myostatin attenuates severity of muscular dystrophy in mdx mice.

Kathryn R Wagner¹, Alexandra C McPherron, Nicole Winik, Se-Jin Lee.

Abstract

Myostatin, a transforming growth factor-beta family member, is a negative regulator of skeletal muscle growth. To explore the therapeutic potential of targeting myostatin in settings of muscle degeneration, we crossed myostatin null mutant mice with mdx mice, a model for Duchenne and Becker muscular dystrophy. Mdx mice lacking myostatin were stronger and more muscular than their mdx counterparts. Diaphragm muscle showed less fibrosis and fatty remodeling, suggesting improved muscle regeneration.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2002 PMID： 12447939 DOI： 10.1002/ana.10385

Source DB: PubMed Journal: Ann Neurol ISSN： 0364-5134 Impact factor: 10.422

Keyword Cloud
Cited

144 in total

1. Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy.

Authors: Kevin J Morine; Lawrence T Bish; Joshua T Selsby; Jeffery A Gazzara; Klara Pendrak; Meg M Sleeper; Elisabeth R Barton; Se-Jin Lee; H Lee Sweeney
Journal: Muscle Nerve Date: 2010-11 Impact factor: 3.217

2. Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type.

Authors: Samuel M Cadena; Kathleen N Tomkinson; Travis E Monnell; Matthew S Spaits; Ravindra Kumar; Kathryn W Underwood; R Scott Pearsall; Jennifer L Lachey
Journal: J Appl Physiol (1985) Date: 2010-05-13

Review 3. Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials.

Authors: Yuko Shimizu-Motohashi; Shouta Miyatake; Hirofumi Komaki; Shin'ichi Takeda; Yoshitsugu Aoki
Journal: Am J Transl Res Date: 2016-06-15 Impact factor: 4.060

4. Recombinant myostatin (GDF-8) propeptide enhances the repair and regeneration of both muscle and bone in a model of deep penetrant musculoskeletal injury.

Authors: Mark W Hamrick; Phonepasong Arounleut; Ethan Kellum; Matthew Cain; David Immel; Li-Fang Liang
Journal: J Trauma Date: 2010-09

5. Regulation of muscle growth by multiple ligands signaling through activin type II receptors.

Authors: Se-Jin Lee; Lori A Reed; Monique V Davies; Stefan Girgenrath; Mary E P Goad; Kathy N Tomkinson; Jill F Wright; Christopher Barker; Gregory Ehrmantraut; James Holmstrom; Betty Trowell; Barry Gertz; Man-Shiow Jiang; Suzanne M Sebald; Martin Matzuk; En Li; Li-Fang Liang; Edwin Quattlebaum; Ronald L Stotish; Neil M Wolfman
Journal: Proc Natl Acad Sci U S A Date: 2005-12-05 Impact factor: 11.205

6. Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis.

Authors: Timothy M Miller; Soo H Kim; Koji Yamanaka; Mark Hester; Priya Umapathi; Hannah Arnson; Liza Rizo; Jerry R Mendell; Fred H Gage; Don W Cleveland; Brian K Kaspar
Journal: Proc Natl Acad Sci U S A Date: 2006-12-12 Impact factor: 11.205

Loss of myostatin attenuates severity of muscular dystrophy in mdx mice.

1. Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy.

2. Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type.

Review 3. Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials.

4. Recombinant myostatin (GDF-8) propeptide enhances the repair and regeneration of both muscle and bone in a model of deep penetrant musculoskeletal injury.

5. Regulation of muscle growth by multiple ligands signaling through activin type II receptors.

6. Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis.

7. Translating mighty mice into neuromuscular therapeutics: is bigger muscle better?

8. Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy.

9. Myostatin directly regulates skeletal muscle fibrosis.

Review 10. Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.